Interventions of Interest
- Suzetrigine (Vertex Pharmaceuticals)
For questions please contact Temiwunmi Shobanke, Program Manager, tshobanke@icer.org.
View the Key Stakeholder List.
Acute Pain
An assessment of suzetrigine
Public Meeting
February 2025
Assessment Status
Open
Upcoming Milestone
Evidence ReportView
Main Review
February 28, 2025
Midwest CEPAC
The Midwest CEPAC’s 2025 public meeting on suzetrigine
Register for Meeting
Public Comment Period
See Full Timeline
12/09/2024 - 01/13/2025
Public Comments on Draft Evidence Report
Related Assessments & Policy Papers.
07/29/2024 - 08/16/2024
Public Comments on Draft Scoping Document
12/09/2024
Draft Evidence Report
02/05/2025
Evidence Report
02/28/2025
Evidence Presentation
03/27/2025
Public Comments
OpenView
Closed